About DiagNodus



Latest News

July 2017: Preliminary results of DiagNodus Pilot Clinical Study on CRC prove DiagNodus concept for CRC detection

February 2017: Pilot Clinical Study on the use of DiagNodus approach for CRC detection initiated

February 2016: "Seal of Excellence" awarded to DiagNodus by the European Commission



About DiagNodus

Company Summary

DiagNodus Ltd is a medical diagnostics company which is pioneering the development of novel non-invasive methods of biological material collection and testing for colorectal disease detection. Producing patient-friendly highly sensitive diagnostic solutions is the principal goal of the company.

DiagNodus devices will provide simple and reliable tools for diagnosis, monitoring and treatment efficiency assessment in the area of inflammatory bowel disease (IBD). They will also save lives by improving population screening efficiency for colorectal cancer (CRC).

Short History

DiagNodus was founded in April 2011 by a group of scientists with extensive experience in the field of colorectal disease. Their aim was to develop entirely non-invasive methods of diagnosing and monitoring diseases which could be used by patients in their own home.

In 2011 DiagNodus applied for its first patent and established its laboratory at the Babraham Research Campus in Cambridge, UK. In 2013 the company applied for its second patent.

In 2012-16 the company organised and successfully completed its first pilot clinical trial addressing several important clinical endpoints in the area of IBD in collaboration with the Department of Gastroenterology of St George's Hospital in London. The completed pilot trial has demonstrated excellent acceptance of DiagNodus method by patients and produced highly impressive results on IBD detection and therapy effect monitoring by the new approach. Results of the study were published as three peer-reviewed papers. The first patent of DiagNodus was granted in 2016.

Current Progress

CRC detection problem constitutes another key target of DiagNodus, and we have won a new grant providing support for initiating this new direction. The study has been started in February 2017, and its early results indicate that our concept for CRC is now proven. This pilot study will be completed in 2018.

The company continues its efforts on raising funds needed for supporting the development of its first products addressing IBD-related clinical endpoints.


Copan Flock Technologies
St George's Healthcare NHS Trust
Medicys Limited
Marks & Clerk LLP




© DiagNodus 2017. All rights reserved. Terms of Use Policy. Privacy Policy
DiagNodus Ltd Registered in England number: 7600875 VAT Number: 121522366
Registered Office: 280 Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT